|
December 20, 2007
Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
December 11, 2007
Nektar Promotes John Nicholson to Serve as Chief Financial Officer
November 28, 2007
Nektar Therapeutics to Present at 2007 BMO Capital Markets Focus on Healthcare Conference
November 14, 2007
Nektar's Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York
November 13, 2007
Pfizer and Nektar Reach Agreement on Exubera(R)
November 13, 2007
Nektar Therapeutics to Webcast R&D Day on November 14th
November 7, 2007
Nektar Therapeutics Announces Third Quarter 2007 Financial Results
October 31, 2007
Nektar to Announce Third Quarter 2007 Financial Results on Wednesday, November 7, 2007, After the Close of U.S. Financial Markets
October 25, 2007
NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
October 18, 2007
Nektar Therapeutics Issues Statement on Exubera
October 10, 2007
Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
October 2, 2007
Nektar Therapeutics President and CEO Howard Robin to Present at 2007 BIO InvestorForum
September 27, 2007
NKTR-102 (PEG-Irinotecan) Demonstrates Significant Anti-Tumor Activity and Improved Pharmacokinetic Profile in Preclinical Studies Presented at ECCO
September 26, 2007
Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting
September 18, 2007
Nektar Therapeutics Creates New PEGylation and Pulmonary Research Units to Drive Innovative Technology-Based Product Pipeline
September 13, 2007
Nektar Therapeutics President and CEO Howard Robin to Present at 2007 UBS Global Life Sciences Conference
September 10, 2007
Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
August 29, 2007
Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
August 23, 2007
Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
August 8, 2007
Nektar Therapeutics Announces Second Quarter 2007 Financial Results
August 6, 2007
Bayer HealthCare and Nektar Therapeutics Launch Global Development and Commercialization Agreement to Fight Gram-Negative Pneumonias
July 26, 2007
First Peer-Reviewed Preclinical and Early Phase 1 Results for NKTR-118 (oral PEG-naloxol) to be Presented at Upcoming Pharmacology and Pain Management Meetings
July 26, 2007
Anti-Tumor Activity and Pharmacokinetic Properties of NKTR-102 (PEG-irinotecan) to be Presented at Upcoming Oncology Meeting
July 25, 2007
Nektar to Announce Second Quarter 2007 Financial Results on Wednesday, August 8, 2007, After the Close of U.S. Financial Markets
May 25, 2007
Nektar Therapeutics President and CEO Howard Robin to Present at Bank of America 2007 Health Care Conference
May 23, 2007
Nektar Announces New Organizational Structure and Spending Reduction Initiatives to Solidify the Company's Leadership Position in PEGylation and Pulmonary Drug Development
May 21, 2007
Nektar Therapeutics Announces Phase 2a Clinical Results Regarding the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative Hospital-Acquired Pneumonia Presented at the Annual American Thoracic Society International Conference
May 9, 2007
Nektar Therapeutics Announces First Quarter 2007 Results
May 9, 2007
Clinical Trial Data (Phase 2a) Regarding Inhaled Amikacin Will Be Presented at American Thoracic Society International Conference
April 27, 2007
Nektar Executives Participating In Upcoming Investor Conferences
April 24, 2007
Nektar to Announce First Quarter 2007 Financial Results On Wednesday, May 9, 2007, After the Close of U.S. Financial Markets
April 9, 2007
Innovative Pulmonary and PEGylation-Based Therapeutic Product Development Drives Business Strategy of Nektar Therapeutics
March 13, 2007
Nektar Initiates Phase 1 Clinical Program Evaluating NKTR-102 (PEG-irinotecan) for Potential to Treat Patients with Refractory Solid Tumors
February 28, 2007
Nektar Announces Financial Results for the Year and Fourth Quarter 2006
February 1, 2007
Merrill Lynch 2007 Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Nektar Corporate Presentation
January 8, 2007
Nektar Appoints Howard W. Robin President and CEO
Investor Advisory |
